Sarah Yee
Pronouns: she/her
Research Mentor(s): Yuanyuan Qiao
Co-Presenter:
Research Mentor School/College/Department: Pathology – Ctr for Translational Pathology / Medicine
Presentation Date: April 20
Presentation Type: Poster
Session: Session 3 – 1:40pm – 2:30 pm
Room: League Ballroom
Authors: Sarah Yee, Xia Jiang, Yuanyuan Qiao
Presenter: 93
Abstract
In this project, we aim to investigate the biology of lipid kinase PIKfyve in the progression of KRAS driven cancers, such as pancreatic cancer. To achieve this, we established pancreatic specific PIKfyve heterozygous or homozygous deletions in a KRAS genetically modified mouse model (GEMM), which included KRAS (G12D); p53 R172H; p48Cre (KPC) GEMM and KRAS (G12D); and p48 Cre (KC) GEMM. With these pancreatic cancer mouse models, we observed pancreatic lesion progression over time and compared that of mice with the presence and absence of PIKfyve. We also inspected the overall survival rate of KPC and KC mice after the deletion of PIKfyve in KPC or KC pancreatic tissue. To do so, we developed a biomarker for autophagy detection in pancreatic tissue. We analyzed tumor inhibition of a small molecule inhibitor of PIKfyve in mice using a human xenograft model and a mouse syngeneic model. In the mouse syngeneic model, we examined efficacy and immune response along with immune checkpoint blockade. After analyzing the data and observations, we found that PIKfyve slowed down the progression of pancreatic lesions for KC mice. We have not yet collected enough data for KPC mice to draw conclusions.
Biomedical Sciences
